tradingkey.logo
搜尋

Amphastar Pharmaceuticals Inc

AMPH
添加自選
19.640USD
-0.460-2.29%
收盤 07/02, 13:00美東報價延遲15分鐘
876.67M總市值
11.49本益比TTM

Amphastar Pharmaceuticals Inc

19.640
-0.460-2.29%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.29%

5天

-6.65%

1月

+6.45%

6月

-25.77%

今年開始到現在

-26.66%

1年

-16.71%

關鍵數據
20.350今開
20.350最高
315.75K成交量
11.49本益比TTM
6.11本益比動
--股利TTM
0.71%換手率
20.100昨收
19.630最低
5.20M成交額
5.50本益比靜
1.13市淨率
0.00%股息率 TTM
4.84%ROA
31.26452週最高
1.10量比
159.52M淨利潤
44.64M總股本
1.7095每股盈餘TTM
0.93Beta
10.39%ROE
16.64552週最低
3.58%振幅
41.08%毛利率
876.67M總市值
4.20回報/風險
2.60%風險率

操作建議

Amphastar Pharmaceuticals Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名64/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為22.00。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Amphastar Pharmaceuticals Inc評分

相關信息

行業排名
64 / 157
全市場排名
166 / 4564
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Amphastar Pharmaceuticals Inc亮點

亮點風險
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
估值合理
公司最新PE估值11.76,處於3年歷史合理位
機構減倉
最新機構持股35.15M股,環比減少11.16%

分析師目標

基於 7 分析師
持有
評級
22.000
目標均價
+6.23%
漲幅空間

Amphastar Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Amphastar Pharmaceuticals Inc簡介

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
公司代碼AMPH
公司Amphastar Pharmaceuticals Inc
CEOZhang (Yongfeng Yongfeng)
網址https://amphastar.com/

常見問題

Amphastar Pharmaceuticals Inc(AMPH)的當前股價是多少?

Amphastar Pharmaceuticals Inc(AMPH)的當前股價是 19.64。

Amphastar Pharmaceuticals Inc 的股票代碼是什麼?

Amphastar Pharmaceuticals Inc的股票代碼是AMPH。

Amphastar Pharmaceuticals Inc股票的52週最高點是多少?

Amphastar Pharmaceuticals Inc股票的52週最高點是31.26。

Amphastar Pharmaceuticals Inc股票的52週最低點是多少?

Amphastar Pharmaceuticals Inc股票的52週最低點是16.64。

Amphastar Pharmaceuticals Inc的市值是多少?

Amphastar Pharmaceuticals Inc的市值是876.67M。

現在Amphastar Pharmaceuticals Inc(AMPH)的股票是買入、持有還是賣出?

根據分析師評級,Amphastar Pharmaceuticals Inc(AMPH)的總體評級為signal_hold,目標價格為22.00。

Amphastar Pharmaceuticals Inc(AMPH)股票的每股收益(EPS TTM)是多少

Amphastar Pharmaceuticals Inc(AMPH)股票的每股收益(EPS TTM)是2.10。